Thyrocare Q4FY25 Revenue Up 21 Percent YoY to Rs 187.2 Cr; PAT Rises 24 Percent to Rs 21.3 Cr

• Consolidated revenue increased by 21% year-over-year (YoY) with Pathology and Radiology segments growing by 23% YoY and 7% YoY respectively
• Total volume in FY25 grew to 167.9 million, largest by far on volume
• Revenue from franchise surged by 22% YoY, and partnership revenue saw 24% YoY growth
• Consolidated gross margin stood at 74%, and normalized EBITDA margin was 35%
• Standalone normalized EBITDA grew by 72% YoY, while PAT* increased by 72% YoY
• Consolidated normalized EBITDA grew by 78% YoY, while PAT* increased by 88% YoY
• Recommended a final dividend of INR 21 per equity share subject to the approval of shareholders at the ensuing shareholders meeting
• Consolidated cash reserves as of March 2025 is INR 191.8 Cr
• Opened new labs in Bhagalpur and Kashmir

Consolidated income statement for Q4FY25 and FY25:

* PAT excluding exceptional item of INR 11.2 Cr pertaining to reversal of deferred tax asset created in previous years against the impairment of investment in NHL.

If you have any objection to this press release content, kindly contact pr.error.rectification@gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.